[{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ BAUSCH + LOMB","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ BAUSCH + LOMB"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Clearside Biomedical","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Clearside Biomedical"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch + Lomb","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch + Lomb"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":2.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":2.5,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Macrogol","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.11,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Lifitegrast","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":2.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":2.5,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Atropine","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bausch & Lomb Incorporated \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Eyenovia"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lutein","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Not Applicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"City Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Bausch & Lomb Incorporated","amount2":0.48999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.48999999999999999,"dosageForm":"Intravitreal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"4","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"InflammX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Tonabersat","moa":"GJs","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"9","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"WB007","moa":"Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"7","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Bausch & Lomb Incorporated"}]
Find Clinical Drug Pipeline Developments & Deals by Bausch & Lomb Incorporated
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
